A Physician Called for Removing Research Barriers While Noting Cannabis Has a Narrow Therapeutic Window
A 1998 review acknowledged marijuana's therapeutic potential but called for modified regulations to enable research, noting the narrow window between therapeutic effects and unpleasant side effects as a major limitation.
Quick Facts
What This Study Found
Writing in the Western Journal of Medicine as California patients were self-medicating with marijuana under Proposition 215, the author assessed the state of medical marijuana evidence and policy.
Clinical studies suggested medical utility for some conditions, but the scientific evidence was described as weak. The author identified several key issues. The regulatory system needed modification to remove barriers to clinical research. Marijuana should be held to the same safety and efficacy standards as other drugs (a flaw in Proposition 215) but should not need to be proven better than existing medications.
The therapeutic window for marijuana and THC between desired effects and unpleasant side effects was narrow, which was a major reason patients discontinued use. The NIH panel recommended high priority for developing a controlled inhaled form of THC. The existence of a natural cannabinoid receptor system in the brain suggested that selective THC analogs could enhance therapeutic effects while minimizing adverse ones.
Key Numbers
NIH identified several conditions meriting further research. The therapeutic window between effect and side effects was described as narrow. Proposition 215 cited as lacking proper efficacy standards.
How They Did This
Commentary and review assessing medical marijuana evidence and policy in the context of California's Proposition 215. Referenced NIH panel recommendations.
Why This Research Matters
This review articulated a middle-ground position that influenced subsequent policy: support research, apply standard evidence requirements, but remove unnecessary regulatory barriers. The observation about the narrow therapeutic window identified a core challenge that still affects cannabis medicine.
The Bigger Picture
The call for a controlled inhaled THC delivery system foreshadowed the development of pharmaceutical cannabis inhalers and vaporizers. The concept of selective THC analogs with fewer side effects anticipated CB2-selective compounds and other targeted cannabinoid therapies being developed today.
What This Study Doesn't Tell Us
A single author's perspective rather than a systematic review. The characterization of evidence as "weak" may have been overstated for some conditions. The focus on pharmaceutical approaches may have undervalued whole-plant preparations.
Questions This Raises
- ?Have research barriers been sufficiently reduced?
- ?Has the therapeutic window problem been solved by modern formulations and delivery methods?
- ?Did the NIH-recommended priorities get adequately funded?
Trust & Context
- Key Stat:
- Narrow therapeutic window between desired effect and side effects was a major limitation
- Evidence Grade:
- A medical journal commentary with review elements. Provides informed perspective but is not a systematic evidence assessment.
- Study Age:
- Published in 1998. Research barriers have been partially reduced, and multiple cannabis-based pharmaceuticals have since been developed.
- Original Title:
- Medical marijuana.
- Published In:
- The Western journal of medicine, 168(6), 540-3 (1998)
- Authors:
- Marmor, J B
- Database ID:
- RTHC-00071
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What was the narrow therapeutic window?
The gap between the dose that produces desired therapeutic effects and the dose that causes unpleasant side effects was small, meaning it was difficult to get the benefit without the side effects.
Did the author support medical marijuana?
Partially. The author supported removing research barriers and acknowledged therapeutic potential but insisted on standard evidence requirements and noted significant limitations.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-law-and-your-rights-complete-guide
- how-much-weed-legally-possess-state-guide
- crossing-state-lines-with-weed-legal-felony
- medical-card-worth-it-2026-benefits-costs
- how-much-weed-legally-grow-home-state-rules
Cite This Study
https://rethinkthc.com/research/RTHC-00071APA
Marmor, J B. (1998). Medical marijuana.. The Western journal of medicine, 168(6), 540-3.
MLA
Marmor, J B. "Medical marijuana.." The Western journal of medicine, 1998.
RethinkTHC
RethinkTHC Research Database. "Medical marijuana." RTHC-00071. Retrieved from https://rethinkthc.com/research/marmor-1998-medical-marijuana
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.